What was studied?
This phase 1/2 study randomized 36 adults with genetically confirmed primary mitochondrial myopathy and assessed walking performance after five days.
What did the researchers report?
The highest-exposure group showed a larger walking-distance change, but the unadjusted comparison with placebo had a P value of 0.053. Other analyses suggested a signal that warranted further investigation.
What are the limits?
The short duration, small sample and differing analyses require caution. The later MMPOWER-3 trial is essential context; a positive exploratory signal should not be presented as established clinical efficacy.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.